Figure 5: In vivo prostate tumor targeting by X770-scFvD2B (A) and X770-scFvD2BGF7.7 (B) probes.
From: In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe
BLI of mice 30 days after LNCaP-lucF cell (0.5 × 106 cells for each dorsal lobe) implantation at the time of intravenous 770-scFv probes (80 μg) injection. Each mouse was imaged by FMT at 24, 72, 96 or 240 hours after X770-scFvD2B (A) or X770-scFvD2BGF7.7 (B) injection. Quantification of the fluorescence signal recovered from FMT imaging at 72 and 96 h were plotted (C) allowing for comparison between X-770scFvD2B (n = 6 at 72 and 96 h) and X770-scFvD2BGF7.7-injected mice (n = 9 at 72 h and n = 4 at 96 h; *** p < 0.01).
